Zions Bancorporation, National Association’s Spyre Therapeutics SYRE Stock Holding History

Zions Bancorporation, National Association’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$89	Buy	+1	New	+$73	﹤0.01%	1622

Other funds holding SYRE

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Zions Bancorporation, National Association's SYRE Position: Q2 2026 in Review

Zions Bancorporation, National Association opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 1 share worth $89. The stake represents ﹤0.01% of the portfolio and ranks #1622 among its holdings.

36 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Zions Bancorporation, National Association held 1 share of Spyre Therapeutics worth $89 as of Q2 2026.
Spyre Therapeutics was a new Zions Bancorporation, National Association position in Q2 2026.
Spyre Therapeutics made up ﹤0.01% of Zions Bancorporation, National Association's portfolio in Q2 2026, its #1622 holding.
36 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Zions Bancorporation, National Association's 13F filing for Q2 2026, filed 31 Jul 2026.